<--- Back to Details
First PageDocument Content
Anticoagulants / Coagulation system / Heparins / Dabigatran / Warfarin / Rivaroxaban / Apixaban / Prothrombin time / Factor X / Chemistry / Hematology / Organic chemistry
Date: 2014-10-01 22:38:52
Anticoagulants
Coagulation system
Heparins
Dabigatran
Warfarin
Rivaroxaban
Apixaban
Prothrombin time
Factor X
Chemistry
Hematology
Organic chemistry

Microsoft Word - stevefb_DOHA_submission_1-2_040112.doc

Add to Reading List

Source URL: pbs.gov.au

Download Document from Source Website

File Size: 41,95 KB

Share Document on Facebook

Similar Documents

*** Drug Safety Alert *** Xarelto (Rivaroxaban) Tablets FDA MedWatch - August 2013 Safety Labeling Changes with revisions to Prescribing Information [PostedThe MedWatch August 2013 Safety Labeling Changes po

*** Drug Safety Alert *** Xarelto (Rivaroxaban) Tablets FDA MedWatch - August 2013 Safety Labeling Changes with revisions to Prescribing Information [PostedThe MedWatch August 2013 Safety Labeling Changes po

DocID: 1t7rk - View Document

Microsoft Word - frommtg draft uspi xarelto  rivaroxaban.doc

Microsoft Word - frommtg draft uspi xarelto rivaroxaban.doc

DocID: 1sPZ1 - View Document

MEDICATION GUIDE XARELTO® (zah-REL-toe) (rivaroxaban) tablets Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide does not take

MEDICATION GUIDE XARELTO® (zah-REL-toe) (rivaroxaban) tablets Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide does not take

DocID: 1scq8 - View Document

Atrial Fibrillation (AFib) Treatment Adherence Following your treatment plan will reduce your risk of AFib-related stroke. it can enter the bloodstream and cause a stroke. A stroke means

Atrial Fibrillation (AFib) Treatment Adherence Following your treatment plan will reduce your risk of AFib-related stroke. it can enter the bloodstream and cause a stroke. A stroke means

DocID: 1pjDF - View Document

QuarterWatch Monitoring FDA MedWatch Reports Why Reports of Serious Adverse Drug Events Continue to Grow October 3, 2012 Data from 2012 Quarter 1

QuarterWatch Monitoring FDA MedWatch Reports Why Reports of Serious Adverse Drug Events Continue to Grow October 3, 2012 Data from 2012 Quarter 1

DocID: 1p1ui - View Document